DelveInsight’s “Alcohol Use Disorder Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Alcohol Use Disorder market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Alcohol Use Disorder drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Alcohol Use Disorder treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Alcohol Use Disorder: An Overview
Alcohol use disorder (AUD) is one of the most common substance use disorders characterized by excessive, uncontrollable drinking that impacts a person physically, emotionally, and socially. It can be mild, moderate, or severe, based on the number of symptoms experienced by an individual. A person with Alcohol Use Disorder may experience both intoxication and withdrawal symptoms such as unstable moods, poor judgment, slurred speech, problems with attention or memory, poor coordination, sweating, rapid heartbeat, hand tremors, seizures, etc.
It has multiple causes, with genetic, physiological, psychological, and social factors all impacting an individual’s behavior. Healthcare professionals use the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria to diagnose and determine the severity of Alcohol Use Disorder and it requires that at least two of the 11 DSM-V diagnostic criteria are present to confirm the diagnosis.
The main goal of Alcohol Use Disorder treatment is either complete abstinence or reduction of heavy drinking. The current treatment options include medication-assisted treatment, behavioral interventions, detox, and psychosocial assistance from rehab and support groups. The mainstay treatment though is psychosocial intervention but with high relapse rates, the best way is to combine pharmacotherapy with psychosocial counseling and intervention.
Alcohol Use Disorder Market Key Facts
-
The United States accounts for the largest Alcohol Use Disorder market size, in comparison to the EU-5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.
-
Among the EU5 countries, Germany had the highest Alcohol Use Disorder market size with approximately USD 35.7 million in 2021. This is expected to further increase, with Germany estimated to capture the maximum market, followed by the UK in 2032.
-
The Alcohol Use Disorder market size in Japan was valued at approximately USD 10.2 million in 2021.
-
In 2021, the 12-month diagnosed prevalent cases of Alcohol Use Disorder were estimated to be 25,027,206 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.6% during the study period (2019-2032).
-
Among the 7MM, the United States accounted for nearly 58% of the total 12-month diagnosed prevalent cases of Alcohol Use Disorder in the 7MM in the year 2021 which is expected to increase further by 2032.
-
Among the EU5 countries, Germany had the highest 12-month diagnosed prevalent cases of Alcohol Use Disorder with 2,541,400+ cases in 2021, while Spain had the lowest 12-month diagnosed prevalent population of Alcohol Use Disorder with 1,326,300+ cases in 2021.
-
In 2021, the 12-month diagnosed prevalent population of Alcohol Use Disorder in Japan was found to be 1,161,900+ which is expected to change for the study period of 2019-2032.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Alcohol Use Disorder pipeline therapies. It also thoroughly assesses the Alcohol Use Disorder market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Alcohol Use Disorder drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Alcohol Use Disorder Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Alcohol Use Disorder epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Alcohol Use Disorder epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Alcohol Use Disorder Epidemiology, Segmented as –
-
12-month Diagnosed Prevalent Cases of AUD in the 7MM [2019-2032]
-
Type-specific Diagnosed Prevalent Cases of AUD in the 7MM [2019-2032]
-
Gender-specific Diagnosed Prevalent Cases of AUD in the 7MM [2019-2032]
Alcohol Use Disorder Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Alcohol Use Disorder market or expected to be launched during the study period. The analysis covers the Alcohol Use Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Alcohol Use Disorder drugs based on their sale and market share.
The report also covers the Alcohol Use Disorder pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Alcohol Use Disorder companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Alcohol Use Disorder Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/alcohol-use-disorder-market
Alcohol Use Disorder Therapeutics Analysis
There is a need for personalized medicine which reduces the craving for alcohol. However, there have been efforts to use precision medicine approaches to tailor pharmacotherapy to individuals with different presentations of Alcohol Use Disorder. But still, there is a large treatment gap in alcohol dependence, and current treatments are only moderately effective in preventing relapse. The need for abstinence and the associated social stigma further complicates the treatment. New treatment modalities, allowing for the reduction of alcohol consumption as a treatment goal, are needed.
The expected launch of potential therapies that include AD04 (ondansetron) (Adial Pharmaceuticals), CORT118335 (mifepristone) (Corcept Therapeutics), and MN-166 (ibudilast) (MediciNova) may address the unmet need in the Alcohol Use Disorder market, increase the market size in the coming years, assisted by an increase in the diagnosed prevalent population of Alcohol Use Disorder.
Several major pharma and biotech companies are developing Alcohol Use Disorder therapies. Currently, Adial Pharmaceuticals is leading the therapeutics market with its Alcohol Use Disorder drug candidates in the most advanced stage of clinical development.
Alcohol Use Disorder Companies Actively Working in the Therapeutics Market Include
Adial Pharmaceuticals, Adial Pharmaceuticals, Alkermes, Arbor Pharmaceuticals, Astellas Pharma, Bioprojet, Bioprojet, Confluence Pharmaceuticals, Corcept Therapeutics, Corcept Therapeutics, Dicerna Pharmaceuticals, Inc., Gilead Sciences, Kinnov Therapeutics, Laboratorio Farmaceutico, Lundbeck, MediciNova, MediciNova, Opiant Pharmaceuticals, Organon, Otsuka Pharmaceuticals, Pfizer, R-Pharm|Synergy Research, and many others.
Emerging and Marketed Alcohol Use Disorder Therapies Covered in the Report Include:
-
Ondansetron: Adial Pharmaceuticals
-
MN-166: MediciNova
-
ANS-6637: Amygdala Neurosciences
-
GET73: Laboratorio Farmaceutico
-
PT150: Pop Test Oncology
-
WIL-1903: Whanin Pharmaceutical
-
CYB003: Cybin
-
BXCL501: BioXcel Therapeutics
-
PT150: Pop Test Oncology
-
DCR-AUD: Dicerna Pharmaceuticals
-
MAP4343: Mapreg
-
KT 110: Kinnov Therapeutics
-
Ibudilast/MN-166: MediciNova
-
AD04/Ondansetron: Adial Pharmaceuticals
-
MN-166 (ibudilast): MediciNova
-
AD04 (ondansetron): Adial Pharmaceuticals
-
CORT118335 (mifepristone): Corcept Therapeutic
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/alcohol-use-disorder-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Alcohol Use Disorder Competitive Intelligence Analysis
4. Alcohol Use Disorder Market Overview at a Glance
5. Alcohol Use Disorder Disease Background and Overview
6. Alcohol Use Disorder Patient Journey
7. Alcohol Use Disorder Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Alcohol Use Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Alcohol Use Disorder Unmet Needs
10. Key Endpoints of Alcohol Use Disorder Treatment
11. Alcohol Use Disorder Marketed Therapies
12. Alcohol Use Disorder Emerging Drugs and Latest Therapeutic Advances
13. Alcohol Use Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Alcohol Use Disorder Market Outlook (In US, EU5, and Japan)
16. Alcohol Use Disorder Companies Active in the Market
17. Alcohol Use Disorder Access and Reimbursement Overview
18. KOL Views on the Alcohol Use Disorder Market
19. Alcohol Use Disorder Market Drivers
20. Alcohol Use Disorder Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/alcohol-use-disorder-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Fallopian Tube Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Fallopian Tube Cancer market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Fallopian Tube Cancer market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research